Company · Healthcare · AI
AI health companion for symptom triage and plain-language advice
Every investor coverage indicates participated in a round AIMEDICS raised.
Companies AIMEDICS acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming AIMEDICS. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
A short GBS Ventures site notice recording that the HypoMon product won an Australian International Design Award, pointing readers to an attached AiMedics press release. No investment, financial or personnel details are given.
AIMEDICS announced $2.04 million in fresh backing from GBS Venture Partners' government-supported IIFF vehicle and a founding backer, to commercialise its HypoMon device that monitors low blood glucose overnight in people with diabetes.